Uncategorized

Full-Day Conference Will Bring Education, Support, and Connection to Families and Healthcare Providers Serving the Duchenne and Becker Community Newport Beach, Calif., September 18, 2025 — CureDuchenne, a global leader in accelerating research and care for Duchenne muscular dystrophy, is proud to announce CureDuchenne Fuerza 2025, an international educational and community-building conference taking place in…

Know More

Event Proceeds Will Advance Research and Support the CureDuchenne Clinic within the Neuromuscular Program at Rady Children’s Health Orange County NEWPORT BEACH, California (September 19, 2025) – CureDuchenne, a global nonprofit dedicated to funding and finding a cure for Duchenne muscular dystrophy, raised over $550,000 at the 14th annual CureDuchenne Golf Shootout. Held on September…

Know More

Chase Rankin was diagnosed with Friedreich’s ataxia in the 7th grade. He is now a graduate from the University of North Carolina at Charlotte, with dreams of becoming an author. Forgive me for stating the obvious: Neuromuscular disease is no fun. It is terrifying, frustrating, deeply saddening, and has countless other negative attributes that combine…

Know More

One thing I love about living in the Midwest is enjoying all four seasons. The last week of summer is nearly over, and autumn officially begins next week. On a walk yesterday, I noticed the first leaves changing and drifting to the ground. Another thing about me is that I love to decorate my house…

Know More

A Phase 1/2 clinical trial testing SAR446268, an experimental gene therapy for myotonic dystrophy type 1 (DM1), is enrolling patients. The trial, dubbed BrAAVe (NCT06844214), is expected to enroll approximately 32 DM1 patients aged 10-50. The study is actively recruiting participants at sites in Florida, New York, and Argentina. It’s sponsored by Sanofi, the company…

Know More

A Fireside Chat with Mike Kelly and Edgewise Therapeutics: A Duchenne Program Update Wednesday, September 3, 2025 WATCH HERE The post WEBINAR: Edgewise appeared first on CureDuchenne.

Know More

A combined regimen of testosterone and growth hormone led to significant improvements in muscle mass, strength, and mobility in men with facioscapulohumeral muscular dystrophy (FSHD) in a clinical trial. The Phase 1/2 STARFISH trial (NCT03123913) evaluated the combination therapy’s safety, tolerability, and potential efficacy in men with FSHD. “We’ve never seen a therapy in FSHD…

Know More

In recognition of Duchenne Muscular Dystrophy Awareness Month in September, the Duchenne Muscular Dystrophy Community Spotlight campaign features a series of stories highlighting the real-life experiences of people affected by Duchenne muscular dystrophy, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MDSpotlight,…

Know More

Living in Pennsylvania with her son, Victoria is an active volunteer with the Speak Foundation and LGMD News magazine as an Assistant Editor. She educates occupational and physical therapists, along with medical students, about her disease and inequities faced in healthcare today. Victoria in front of Montgomery Elementary School Everyone finds their voice at different…

Know More

Ribbon-Cutting Ceremony Marks a Major Step Forward in Expanding Access to Advanced Care and Cutting-Edge Treatment for Families Across Southern California NEWPORT BEACH, Calif. (September 15, 2025) – CureDuchenne and Rady Children’s Health officially dedicated the CureDuchenne Clinic within the Neuromuscular Program at Rady Children’s Health Orange County with a ribbon-cutting ceremony held during Muscular…

Know More